{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T03:37:32Z","timestamp":1787369852912,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T00:00:00Z","timestamp":1551830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12882-019-1250-0","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T10:02:55Z","timestamp":1551866575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Epidemiology and health outcomes associated with hyperkalemia in a primary care setting in England"],"prefix":"10.1186","volume":"20","author":[{"given":"Laura","family":"Horne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhtar","family":"Ashfaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"MacLachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin","family":"Sinsakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"LoCasale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Wetmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,6]]},"reference":[{"key":"1250_CR1","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrneph.2014.168","volume":"10","author":"CP Kovesdy","year":"2014","unstructured":"Kovesdy CP. Management of hyperkalaemia in chronic kidney disease. Nat Rev Nephrol. 2014;10:653\u201362.","journal-title":"Nat Rev Nephrol"},{"key":"1250_CR2","unstructured":"National Kidney Foundation. Clinical update on hyperkalemia: a chronic risk for CKD patients and a potential barrier to recommended CKD treatment. 2014. \n                    https:\/\/www.kidney.org\/sites\/default\/files\/02-10-6785_HBE_Hyperkalemia_Bulletin.pdf\n                    \n                  . Accessed 16 Jan 2018."},{"key":"1250_CR3","unstructured":"National Kidney Foundation. Hyperkalemia: survey of awareness and experience among adults with CKD. 2017. \n                    https:\/\/www.kidney.org\/sites\/default\/files\/HyperkalemiaReport1.pdf\n                    \n                  . Accessed 16 Jan 2018."},{"key":"1250_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/CE.S129555","volume":"12","author":"MV Beccari","year":"2017","unstructured":"Beccari MV, Meaney CJ. Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review. Core Evid. 2017;12:11\u201324.","journal-title":"Core Evid"},{"key":"1250_CR5","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.amjmed.2012.08.016","volume":"126","author":"Z Harel","year":"2013","unstructured":"Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med. 2013;126:264 e9\u201324.","journal-title":"Am J Med"},{"key":"1250_CR6","volume-title":"US prescribing information","author":"Veltassa (patiromer)","year":"2016","unstructured":"Veltassa (patiromer). US prescribing information. Redwood City, CA: Relypsa, Inc.; 2016."},{"key":"1250_CR7","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","volume":"169","author":"LM Einhorn","year":"2009","unstructured":"Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169:1156\u201362.","journal-title":"Arch Intern Med"},{"key":"1250_CR8","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.2215\/CJN.01150112","volume":"7","author":"PA Sarafidis","year":"2012","unstructured":"Sarafidis PA, Blacklock R, Wood E, Rumjon A, Simmonds S, Fletcher-Rogers J, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol. 2012;7:1234\u201341.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1250_CR9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s11897-009-0037-1","volume":"6","author":"AS Desai","year":"2009","unstructured":"Desai AS. Hyperkalemia in patients with heart failure: incidence, prevalence, and management. Curr Heart Fail Rep. 2009;6:272\u201380.","journal-title":"Curr Heart Fail Rep"},{"key":"1250_CR10","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ije\/dyv098","volume":"44","author":"E Herrett","year":"2015","unstructured":"Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44:827\u201336.","journal-title":"Int J Epidemiol"},{"key":"1250_CR11","unstructured":"National Health Service (NHS). Hospital Episode Statistics. \n                    https:\/\/digital.nhs.uk\/data-and-information\/data-tools-and-services\/data-services\/hospital-episode-statistics\n                    \n                  . Accessed 15 June 2017."},{"key":"1250_CR12","unstructured":"National Health Service (NHS). Linked HES-ONS mortality data. \n                    https:\/\/digital.nhs.uk\/data-and-information\/data-tools-and-services\/data-services\/linked-hes-ons-mortality-data\n                    \n                  . Accessed 15 June 2017."},{"key":"1250_CR13","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","volume":"53","author":"AS Levey","year":"2007","unstructured":"Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53:766\u201372.","journal-title":"Clin Chem"},{"key":"1250_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ijcard.2017.07.035","volume":"245","author":"E Nilsson","year":"2017","unstructured":"Nilsson E, Gasparini A, \u00c4rnl\u00f6v J, Xu H, Henriksson KM, Coresh J, et al. Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system. Int J Cardiol. 2017;245:277\u201384.","journal-title":"Int J Cardiol"},{"key":"1250_CR15","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40264-014-0196-1","volume":"37","author":"C Ben Salem","year":"2014","unstructured":"Ben Salem C, Badreddine A, Fathallah N, Slim R, Hmouda H. Drug-induced hyperkalemia. Drug Saf. 2014;37:677\u201392.","journal-title":"Drug Saf"},{"key":"1250_CR16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2215\/CJN.07821109","volume":"5","author":"MR Weir","year":"2010","unstructured":"Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5:531\u201348.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1250_CR17","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.2215\/CJN.08580813","volume":"10","author":"BF Palmer","year":"2015","unstructured":"Palmer BF. Regulation of potassium homeostasis. Clin J Am Soc Nephrol. 2015;10:1050\u201360.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1250_CR18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1258\/acb.2011.011281","volume":"49","author":"D Wile","year":"2012","unstructured":"Wile D. Diuretics: a review. Ann Clin Biochem. 2012;49:419\u201331.","journal-title":"Ann Clin Biochem"},{"key":"1250_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1365-2125.2009.03537.x","volume":"69","author":"E Herrett","year":"2010","unstructured":"Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the general practice research database: a systematic review. Br J Clin Pharmacol. 2010;69:4\u201314.","journal-title":"Br J Clin Pharmacol"},{"key":"1250_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-002011","volume":"2","author":"JL Fleet","year":"2012","unstructured":"Fleet JL, Shariff SZ, Gandhi S, Weir MA, Jain AK, Garg AX. Validity of the international classification of diseases 10th revision code for hyperkalaemia in elderly patients at presentation to an emergency department and at hospital admission. BMJ Open. 2012;2:e002011.","journal-title":"BMJ Open"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1250-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1250-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1250-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T19:11:35Z","timestamp":1583349095000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1250-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,6]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1250"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1250-0","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,6]]},"assertion":[{"value":"6 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All research undertaken using data obtained from the Clinical Practice Research Database (CPRD) is approved by, as appropriate, an ethics committee, a scientific committee, and the National Information Governance Board Ethics and Confidentiality Committee. The study protocol (protocol number: 16_217R2) was approved by the Independent Scientific Advisory Committee from the CPRD. The CPRD adheres to all applicable UK and European laws, National Health Service Guidelines, and other guidelines governing research. All CPRD data is anonymized, and additional compliance safeguards put in place include, but are not limited to, Charters, Privacy Enhancing Technologies, and legal arrangements, among others.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LH is a consultant to AstraZeneca and owns AstraZeneca stock. AA was a full-time employee of AstraZeneca at the time of study conduct. SM is an employee of Evidera who provides consultancy services to AstraZeneca. MS and LQ are employees and stockholders of AstraZeneca. RL was an employee of AstraZeneca and owned AstraZeneca stock at the time of the study conduct. JBW serves on the speakers\u2019 bureau for OPKO Renal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"85"}}